Related Experiment Video
Updated: Oct 1, 2026

Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research
Published on: November 3, 2023
Efficacy of Remimazolam for Anesthesia in Patients Undergoing Renal Allograft Transplantation: A Randomized
Mingming Han1, Dandan Sun1, Danjun Lu1
1Department of Anesthesiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, People's Republic of China.
Purpose:
As a novel benzodiazepine sedative, remimazolam has demonstrated favorable anesthetic properties. However, its clinical performance in patients undergoing renal allograft transplantation remains undetermined. This study aimed to evaluate the efficacy of remimazolam for anesthesia in patients undergoing renal allograft transplantation, with the incidence of hypotension during induction as the primary endpoint.
Patients And Methods:
Sixty patients scheduled for elective living-related renal transplantation were enrolled. The participants were randomly allocated into two groups (n=30 each): the propofol group (Group P) and the remimazolam group (Group R). Groups P and R received propofol and remimazolam, respectively, for anesthesia induction and maintenance. The patients' hemodynamic parameters, postoperative recovery outcomes, adverse reactions, and pharmacokinetic parameters of the sedative drugs were recorded and compared between groups.
Results:
Compared with propofol, remimazolam has a longer onset time, but provides better hemodynamic stability, more rapid metabolism, negligible injection pain, and no significant impact on hepatic or renal function.
Conclusion:
Despite its prolonged onset time, remimazolam provides better hemodynamic stability and less injection pain than propofol in patients undergoing allogeneic renal transplantation, with comparable recovery outcomes. Its rapid metabolism is evidenced by a prompt decline in plasma concentration following discontinuation.